Patent ID: 8198236
Filing Date: 2012-06-12
Classification: A61K,A61P

Abstract:
1. A method of treating cancer in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of an oligopeptide consisting of between 10 contiguous amino acids and about 70 contiguous amino acids, wherein the oligopeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, a sequence sharing at least 70% sequence identity with SEQ ID NO: 1, a sequence sharing at least 70% sequence identity with SEQ ID NO: 2, a sequence sharing at least 70% sequence identity with SEQ ID NO: 3, a sequence sharing at least 70% sequence identity with SEQ ID NO: 4, a sequence sharing at least 70% sequence identity with SEQ ID NO: 5, a sequence sharing at least 70% sequence identity with SEQ ID NO: 6, a sequence sharing at least 70% sequence identity with SEQ ID NO: 7, a sequence sharing at least 70% sequence identity with SEQ ID NO: 8, a sequence sharing at least 70% sequence identity with SEQ ID NO: 9, a sequence sharing at least 70% sequence identity with SEQ ID NO: 10, a sequence sharing at least 70% sequence identity with SEQ ID NO: 11, a sequence sharing at least 70% sequence identity with SEQ ID NO: 12, a sequence sharing at least 70% sequence identity with SEQ ID NO: 13, a sequence sharing at least 70% sequence identity with SEQ ID NO: 14, a sequence sharing at least 70% sequence identity with SEQ ID NO: 15, a sequence sharing at least 70% sequence identity with SEQ ID NO: 16, a sequence sharing at least 70% sequence identity with SEQ ID NO: 17, a sequence sharing at least 70% sequence identity with SEQ ID NO: 18, a sequence sharing at least 70% sequence identity with SEQ ID NO: 19, a sequence sharing at least 70% sequence identity with SEQ ID NO: 20, a sequence sharing at least 70% sequence identity with SEQ ID NO: 21, a sequence sharing at least 70% sequence identity with SEQ ID NO: 22, a sequence sharing at least 70% sequence identity with SEQ ID NO: 23, a sequence sharing at least 70% sequence identity with SEQ ID NO: 24, a sequence sharing at least 70% sequence identity with SEQ ID NO: 25, a sequence sharing at least 70% sequence identity with SEQ ID NO: 26, a sequence sharing at least 70% sequence identity with SEQ ID NO: 27, a sequence sharing at least 70% sequence identity with SEQ ID NO: 28, a sequence sharing at least 70% sequence identity with SEQ ID NO: 29, a sequence sharing at least 70% sequence identity with SEQ ID NO: 30, a sequence sharing at least 70% sequence identity with SEQ ID NO: 31, a sequence sharing at least 70% sequence identity with SEQ ID NO: 32, a sequence sharing at least 70% sequence identity with SEQ ID NO: 33, a sequence sharing at least 70% sequence identity with SEQ ID NO: 34, a sequence sharing at least 70% sequence identity with SEQ ID NO: 35, a sequence sharing at least 70% sequence identity with SEQ ID NO: 36, a sequence sharing at least 70% sequence identity with SEQ ID NO: 37 and a sequence sharing at least 70% sequence identity with SEQ ID NO: 38, wherein the oligopeptide antagonizes binding of a Wnt ligand to at least one of LRP5 and LRP6.